Genesys International Valuation
Is GENESYS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GENESYS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GENESYS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GENESYS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GENESYS?
Other financial metrics that can be useful for relative valuation.
What is GENESYS's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹22.51b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 13.1x |
Enterprise Value/EBITDA | 35.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GENESYS's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.1x | ||
ACCELYA Accelya Solutions India | 4.9x | n/a | ₹24.8b |
SAKSOFT Saksoft | 3.7x | n/a | ₹28.0b |
532365 Dynacons Systems & Solutions | 1.6x | n/a | ₹16.0b |
EXPLEOSOL Expleo Solutions | 2.2x | 19.5% | ₹20.6b |
GENESYS Genesys International | 13x | n/a | ₹22.5b |
Price-To-Sales vs Peers: GENESYS is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does GENESYS's PE Ratio compare vs other companies in the IN IT Industry?
Price-To-Sales vs Industry: GENESYS is expensive based on its Price-To-Sales Ratio (13x) compared to the Indian IT industry average (4.4x).
Price to Sales Ratio vs Fair Ratio
What is GENESYS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 13x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GENESYS's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.